Felsenberg Dieter, Boonen Steven
Department of Radiology and Nuclear Medicine, Centre of Muscle and Bone Research, Charité-Campus Benjamin Franklin, Free & Humboldt University, Berlin, Germany.
Clin Ther. 2005 Jan;27(1):1-11. doi: 10.1016/j.clinthera.2004.12.020.
BACKGROUND: Bone mineral density (BMD) measurements are the standard tool in the diagnosis of osteoporosis. However, recent developments in bone research show that a BMD measurement, while still important in a clinical setting, is in itself insufficient to accurately predict fracture risk or measure treatment effects of an antiosteoporosis drug. Clinical experience with patient follow-up strongly suggests that bone quality must also be taken into account. OBJECTIVES: The objectives of this paper are. (1) to describe the determinants of bone strength (structural and material properties of bone, both of which are affected by bone turnover) and their interrelationships, and (2) to provide a schematic explanation of these determinants of bone strength, which in this paper is referred to as the Bone Quality Framework. METHODS: Relevant information from the primary literature and review articles published in the English language were identified through a MEDLINE search of the medical literature, from 1990 to October 2004, in the fields of bone density, bone strength, bone quality, fracture risk, and fracture risk reduction. Additional publications were identified from the reference lists of the resulting articles. Identified publications relevant to the objectives of this review paper were selected. CONCLUSIONS: The Bone Quality Framework is presented in this paper as a means of summarizing and explaining the determinants of bone strength. In this framework, bone quality can be understood as an umbrella term that describes the set of characteristics that influence bone strength and explains the interrelationships of these characteristics. Bone strength depends on the structural and material properties of bone, both of which are influenced by the rate of bone turnover. Not all determinants of bone strength are well represented by a BMD measurement. The Bone Quality Framework presents an opportunity to examine all the determinants of bone strength. Greater understanding of the concept of bone quality will ultimately help improve the assessment of fracture risk and monitoring of patients receiving treatment for osteoporosis.
背景:骨密度(BMD)测量是骨质疏松症诊断的标准工具。然而,骨研究的最新进展表明,BMD测量虽然在临床环境中仍然很重要,但就其本身而言,不足以准确预测骨折风险或衡量抗骨质疏松药物的治疗效果。对患者随访的临床经验强烈表明,骨质量也必须加以考虑。 目的:本文的目的是:(1)描述骨强度的决定因素(骨的结构和材料特性,二者均受骨转换影响)及其相互关系;(2)对这些骨强度的决定因素提供一个示意性解释,在本文中称为骨质量框架。 方法:通过对1990年至2004年10月期间发表在英文医学文献中的原始文献和综述文章进行MEDLINE检索,确定在骨密度、骨强度、骨质量、骨折风险和降低骨折风险等领域的相关信息。从所得文章的参考文献列表中识别出其他出版物。选择与本综述文章目的相关的已识别出版物。 结论:本文提出骨质量框架,作为总结和解释骨强度决定因素的一种方式。在此框架中,骨质量可理解为一个总括性术语,用于描述影响骨强度的一系列特征,并解释这些特征的相互关系。骨强度取决于骨的结构和材料特性,二者均受骨转换速率的影响。并非所有骨强度的决定因素都能通过BMD测量得到充分体现。骨质量框架为检查骨强度的所有决定因素提供了一个契机。对骨质量概念的更深入理解最终将有助于改善骨折风险评估以及对接受骨质疏松症治疗患者的监测。
Curr Med Res Opin. 2004-3
Curr Med Res Opin. 2005-7
J Clin Rheumatol. 2006-4
Clin Calcium. 2004-10
Clin Lab Med. 2000-9
Clin Calcium. 2005-4
Clin Calcium. 2008-3
Best Pract Res Clin Rheumatol. 2005-12
Ther Adv Endocrinol Metab. 2025-5-29
J Funct Biomater. 2024-3-31
Curr Osteoporos Rep. 2023-10
Arch Endocrinol Metab. 2022-11-11